Fibrosis, the pathological end stage of chronic inflammatory diseases, results from extracellular matrix deposition by fibrogenic fibroblasts. In this issue of Cell Stem Cell, Sobecki et al. (2022) develop a novel vaccination-based immunotherapy against fibrogenic progenitor-restricted antigens, leading to the regression of fibrosis in concert with liver and lung regeneration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.stem.2022.09.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Turning the Tide of Viral Hepatitis-Induced Acute Liver Failure: The Role of Standard Volume Plasma Exchange in Adults and Children.
Transfus Clin Biol
January 2025
Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun 248140 Uttarakhand, India.
Introduction: Therapeutic plasma exchange (TPE) is the most widely used artificial liver support system in liver failure patients.
Cases: We report five cases of viral hepatitis induced ALF 3 adult (case I, II, III) and two pediatric (case IV and V) patients not adequately responding to standard medical treatment (SMT). Case I and II were acute hepatitis B infections while case III was an antenatal case with acute hepatitis E.
Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.
Front Immunol
December 2024
Department of Anesthesiology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Background: Lung adenocarcinoma (LUAD) is a heterogeneous tumor characterized by diverse genetic and molecular alterations. Developing a multi-omics-based classification system for LUAD is urgently needed to advance biological understanding.
Methods: Data on clinical and pathological characteristics, genetic alterations, DNA methylation patterns, and the expression of mRNA, lncRNA, and microRNA, along with somatic mutations in LUAD patients, were gathered from the TCGA and GEO datasets.
Turning the tide on healthy eating.
Br J Gen Pract
December 2024
Flexitarian south-east coast GP. Email:
Recent achievements and future directions of anti-obesity medications.
Lancet Reg Health Eur
December 2024
Institute for Diabetes and Obesity, Helmholtz Munich, Neuherberg, Germany.
Article Synopsis
- Recent advancements in pharmacological treatments for obesity, particularly with GLP-1 agonists and unimolecular peptides, have shifted the perception of obesity management from 'Mission Impossible' to a more feasible approach with promising results.
- These novel treatments not only aid in weight loss and blood sugar control for those with obesity and type 2 diabetes, but also show potential benefits for other health issues like neurodegenerative diseases and cardiovascular conditions.
- The review discusses the progress made in incretin-based therapies, their effectiveness and safety, as well as limitations and side effects associated with their use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!